{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:05:06Z","timestamp":1790424306247,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare, dangerous, life-threatening disease characterized by microangiopathic hemolytic anemia and thrombocytopenia, along with organ dysfunction due to microangiopathy-related ischemia. Plasma exchange and steroids are used for initial treatment, and rituximab is often used in refractive patients. Caplacizumab, cyclophosphamide, and splenectomy are among other treatment options. It has been reported that bortezomib, a proteasome inhibitor, can be used in the management of refractory acquired TTP. Herein, we present a 16-year-old female patient who was monitored for acquired TTP and treated with high-dose steroids, plasma exchange, rituximab, cyclophosphamide, and N-acetylcysteine but developed renal, cardiac, gastrointestinal, and neurologic complications. The girl was then successfully treated with bortezomib, and she has been monitored in remission for 6 months. We consider that bortezomib is a beneficial treatment, especially in patients with refractory TTP.<\/jats:p>","DOI":"10.1097\/mph.0000000000002026","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T02:01:09Z","timestamp":1607652069000},"page":"e587-e591","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Successful Treatment With Bortezomib for Refractory and Complicated Acquired Thrombotic Thrombocytopenic Purpura in an Adolescent Girl"],"prefix":"10.1097","volume":"43","author":[{"given":"Ebru","family":"Azapa\u011fasi","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Uysal Yazici","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilg\u00fcn","family":"Ero\u011flu","sequence":"additional","affiliation":[{"name":"Divion of Pediatric Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Kirikklale University Faculty of Medicine, Kirikkale, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge","family":"Kucur","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Dr Sami Ulus Maternity and Children\u2019s Training and Research Hospital, Ankara"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Fettah","sequence":"additional","affiliation":[{"name":"Divion of Pediatric Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int J Hematol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13107","article-title":"Pediatric thrombotic thrombocytopenic purpura","volume":"101","author":"Joly","year":"2018","journal-title":"Eur J Haematol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How i treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"Adamts13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of adamts13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J Haematol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ejh.12206","article-title":"Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib","volume":"92","author":"van Balen","year":"2014","journal-title":"Eur J Haematol"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/trf.13465","article-title":"Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib","volume":"56","author":"Patel","year":"2016","journal-title":"Transfusion"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"bcr2016215491","DOI":"10.1136\/bcr-2016-215491","article-title":"Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura","volume":"2016","author":"Acedillo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Haematol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/jth.13764","article-title":"Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics","volume":"15","author":"Saha","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the french thrombotic microangiopathies reference center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jgh3.12156","article-title":"Thrombotic thrombocytopenic purpura: a rare complication of acute pancreatitis","volume":"3","author":"Shah","year":"2019","journal-title":"JGH Open"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00277-016-2804-x","article-title":"Bortezomib therapy in patients with relapsed\/refractory acquired thrombotic thrombocytopenic purpura","volume":"95","author":"Eskazan","year":"2016","journal-title":"Ann Hematol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2000.01941.x","article-title":"Management of thrombotic thrombocytopenic purpura","volume":"109","author":"Rock","year":"2000","journal-title":"Br J Haematol"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the oklahoma registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1537-2995.2012.03944.x","article-title":"Cyclosporin a therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature","volume":"53","author":"Yilmaz","year":"2013","journal-title":"Transfusion"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the french tma reference center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2006.12.038","article-title":"Treatment with rituximab in benign and malignant hematologic disorders in children","volume":"150","author":"Giulino","year":"2007","journal-title":"J Pediatr"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1532\/IJH97.04187","article-title":"Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura","volume":"81","author":"Kosugi","year":"2005","journal-title":"Int J Hematol"},{"key":"R27-20250804","first-page":"518","article-title":"Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. a case report and concise review of the literature","volume":"137","author":"Rufer","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2141.2004.04836.x","article-title":"Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"124","author":"Yomtovian","year":"2004","journal-title":"Br J Haematol"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jca.20172","article-title":"Rituximab as an adjunct to plasma exchange in ttp: a report of 12 cases and review of literature","volume":"23","author":"Jasti","year":"2008","journal-title":"J Clin Apher"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von willebrand factor, adamts13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of n-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"e27737","DOI":"10.1002\/pbc.27737","article-title":"Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura","volume":"66","author":"Bhoopalan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJMc1301264","article-title":"Antibody depletion by bortezomib through blocking of antigen presentation","volume":"368","author":"Park","year":"2013","journal-title":"N Engl J Med"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","article-title":"Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura","volume":"2018","author":"Dane","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:12:57Z","timestamp":1754338377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002026","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"2020-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}